SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RVMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 330.91M
March 31, 2026 261.28M
December 31, 2025 195.04M
September 30, 2025 156.57M
June 30, 2025 127.76M
March 31, 2025 108.90M
December 31, 2024 96.72M
September 30, 2024 100.75M
June 30, 2024 92.31M
March 31, 2024 85.24M
December 31, 2023 75.62M
September 30, 2023 54.29M
June 30, 2023 49.21M
March 31, 2023 44.77M
December 31, 2022 40.58M
September 30, 2022 38.37M
Date Value
June 30, 2022 35.72M
March 31, 2022 32.82M
December 31, 2021 30.45M
September 30, 2021 27.58M
June 30, 2021 25.13M
March 31, 2021 22.93M
December 31, 2020 21.43M
September 30, 2020 19.76M
June 30, 2020 17.53M
March 31, 2020 15.16M
December 31, 2019 12.41M
September 30, 2019 12.08M
June 30, 2019 8.976M
March 31, 2019 6.251M
December 31, 2018 3.835M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Tango Therapeutics, Inc. 56.51M
Erasca, Inc. 41.80M
Moderna, Inc. 965.00M
Arrowhead Pharmaceuticals, Inc. 172.57M
Intellia Therapeutics, Inc. 136.25M